Definium Therapeutics, Inc.

NASDAQ:DFTX

Biotechnology

Healthcare
$29.12 -1.67%

-$0.41 today

Market cap
$3.99B
Beta
2.38
P/E (TTM)
-11.0
EPS (TTM)
-$2.18
52W Low $12.88High $26.15

Volume 1.91M

Average 2.67M

DFTX Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Definium Therapeutics, Inc.NASDAQ: DFTX

Accounts Payables · Q3 FY2026 · quarter ended Sep 2026

Accounts payables declines year over year

Q3 FY2026 accounts payables of $2.31M fell 40.7% year over year, ahead of the -81.9% change in trailing-twelve-month accounts payables.

Context

  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -40.7% holds above the trailing-twelve-month pace of -81.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$2.31M+1527.2% QoQ
Last fiscal yearDec 2025
$3.34M+257.0% YoY
LTMSep 2026
$1.08M-81.9% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-40.7%——
1 year+257.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
3.34M USD
Year-over-year change
+257.0%
4-year CAGR
+27.0%

Accounts Payables vs competitors

How DFTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -81.9% is the 5th highest of 8, against a peer median of +249.6%.
DFTX Competitors
Accounts Payables for DFTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$15.8M USD-200.0%+45.9%—
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$12.66M USD-141.8%—1.6%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$5.43M USD———
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$4.34M USD+345.5%—21.7%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$4M USD+845.6%——
ANROAlto Neuroscience, Inc.LTM Mar 2026$1.98M USD+327.2%-39.7%—
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$1.08M USD-81.9%——
NERVMinerva Neurosciences, Inc.LTM Jun 2026$423.37K USD—+6.2%—
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$190K USD+249.6%——
GHRSGH Research PLCLTM Mar 2026$0 USD———
ATHEAlterity Therapeutics LimitedFY2025A$0 AUD-100.0%—0.0%
Peer median (excluding DFTX) —+249.6%+6.2%1.6%

Competitors are the stored peer set for DFTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(93.04M)(56.8M)(95.73M)(108.68M)(183.79M)
Depreciation & Amortization2.62M3.18M3.16M527K0
Deferred Income Tax(1.16M)0(2.03M)00
Stock-Based Compensation42.72M13.71M15.49M16.91M20.1M
Change in Working Capital1.88M(3.78M)6.28M(3.34M)9.44M
Accounts Receivables00000
Inventory00000
Accounts Payables1.28M(2.06M)2.03M(2.13M)3.34M
Other Working Capital598K(1.73M)4.26M(1.22M)6.1M
Other Non-Cash Items1.16M(6.45M)8.46M15.45M22.7M
Operating Cash Flow(45.82M)(50.14M)(64.37M)(79.13M)(131.56M)
Capital Expenditures00000
Acquisitions (Net)(297K)0000
Purchases of Investments0000(268.36M)
Sales of Investments0000116.75M
Other Investing Activities00000
Investing Cash Flow(297K)000(151.61M)
Debt Repayment0014.16M10.86M20M
Common Stock Issued81.92M42.3M7.53M250M259.9M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities16.9M16.75M163K(7.66M)(12.63M)
Financing Cash Flow98.82M59.05M21.85M253.2M267.27M
Effect of Forex Changes742K(309K)79K(30K)(7K)
Net Change in Cash53.45M8.6M(42.44M)174.04M(15.9M)
Free Cash Flow(45.82M)(50.14M)(64.37M)(79.13M)(131.56M)

Definium Therapeutics, Inc.

NASDAQ:DFTX

Intrinsic Alpha fair value

Locked

Current Price

$29.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.